Seoulin Bioscience Co.,Ltd. (KOSDAQ:038070)
6,590.00
-140.00 (-2.08%)
Last updated: Mar 24, 2025
Seoulin Bioscience Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Net Income | 2,914 | -117.55 | 10,159 | 15,589 | 4,893 | Upgrade
|
Depreciation & Amortization | 1,365 | 1,287 | 1,017 | 1,930 | 1,984 | Upgrade
|
Loss (Gain) From Sale of Assets | 65.11 | 31.42 | 0.65 | -14,092 | -0.27 | Upgrade
|
Asset Writedown & Restructuring Costs | 152.6 | - | 393.03 | 1,044 | - | Upgrade
|
Loss (Gain) From Sale of Investments | -1,986 | 4,966 | -2,011 | -160.11 | -118.2 | Upgrade
|
Loss (Gain) on Equity Investments | -139.95 | -85.1 | -84.76 | -114.5 | -89.12 | Upgrade
|
Provision & Write-off of Bad Debts | 328.55 | -61.68 | 452.77 | 27.35 | -104.66 | Upgrade
|
Other Operating Activities | 424.55 | 1,869 | -4,163 | 5,535 | -1,107 | Upgrade
|
Change in Accounts Receivable | 5,504 | -6,269 | 3,048 | -1,314 | -489.6 | Upgrade
|
Change in Inventory | -4,345 | -7,528 | -3,918 | -3,025 | 220.75 | Upgrade
|
Change in Accounts Payable | -6,447 | 2,936 | -2,163 | 4,435 | -1,830 | Upgrade
|
Change in Other Net Operating Assets | -2,447 | 3,903 | -7,086 | -938.58 | 326.52 | Upgrade
|
Operating Cash Flow | -4,611 | 930.57 | -4,356 | 8,918 | 3,684 | Upgrade
|
Operating Cash Flow Growth | - | - | - | 142.03% | -49.67% | Upgrade
|
Capital Expenditures | -48.45 | -945.51 | -461.62 | -933.29 | -401.34 | Upgrade
|
Sale of Property, Plant & Equipment | 0.49 | 123.75 | 59.86 | 20,418 | 13.26 | Upgrade
|
Cash Acquisitions | - | - | -35.23 | - | - | Upgrade
|
Divestitures | 0.08 | - | - | - | - | Upgrade
|
Sale (Purchase) of Intangibles | -13.97 | - | -245.42 | -669.69 | -541.34 | Upgrade
|
Investment in Securities | 6,429 | 28,576 | -1,904 | -49,934 | 1,608 | Upgrade
|
Other Investing Activities | -12.68 | -204.53 | -44.07 | -312.18 | 9.21 | Upgrade
|
Investing Cash Flow | 6,389 | 27,526 | -2,665 | -31,499 | 708.85 | Upgrade
|
Short-Term Debt Issued | 3,000 | 550.5 | 55.95 | 125.73 | 15.7 | Upgrade
|
Long-Term Debt Issued | - | 0.13 | - | 30,000 | 500 | Upgrade
|
Total Debt Issued | 3,000 | 550.63 | 55.95 | 30,126 | 515.7 | Upgrade
|
Short-Term Debt Repaid | -50 | -40.18 | -35.27 | -38.5 | -11 | Upgrade
|
Long-Term Debt Repaid | -8,475 | -22,083 | -296.05 | -229.77 | -16.93 | Upgrade
|
Total Debt Repaid | -8,525 | -22,123 | -331.32 | -268.27 | -27.93 | Upgrade
|
Net Debt Issued (Repaid) | -5,525 | -21,573 | -275.37 | 29,857 | 487.77 | Upgrade
|
Repurchase of Common Stock | -1,092 | -142.62 | -198.94 | -80.6 | -168.98 | Upgrade
|
Dividends Paid | -836.16 | -1,062 | -798.49 | -769.16 | -721.15 | Upgrade
|
Other Financing Activities | - | -0 | 2,350 | -0 | - | Upgrade
|
Financing Cash Flow | -7,453 | -22,778 | 1,077 | 29,008 | -402.37 | Upgrade
|
Foreign Exchange Rate Adjustments | 22.54 | -75.93 | -30.2 | 47.83 | -35.7 | Upgrade
|
Miscellaneous Cash Flow Adjustments | 0 | - | -0 | 0 | 0 | Upgrade
|
Net Cash Flow | -5,653 | 5,603 | -5,974 | 6,475 | 3,955 | Upgrade
|
Free Cash Flow | -4,660 | -14.95 | -4,817 | 7,984 | 3,283 | Upgrade
|
Free Cash Flow Growth | - | - | - | 143.19% | -53.44% | Upgrade
|
Free Cash Flow Margin | -6.18% | -0.02% | -4.60% | 9.91% | 5.04% | Upgrade
|
Free Cash Flow Per Share | -534.60 | -1.71 | -442.90 | 908.19 | 373.19 | Upgrade
|
Cash Interest Paid | 48.25 | 20.79 | 10.83 | 14.23 | 18.66 | Upgrade
|
Cash Income Tax Paid | 1,295 | 1,408 | 5,837 | 668.25 | 2,634 | Upgrade
|
Levered Free Cash Flow | -8,710 | -12,310 | -12,853 | 27,527 | 1,586 | Upgrade
|
Unlevered Free Cash Flow | -8,504 | -10,759 | -11,424 | 27,667 | 1,597 | Upgrade
|
Change in Net Working Capital | 10,402 | 12,659 | 17,482 | -22,683 | 2,238 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.